Q182 – 188: Current GVHD Status

*Combined Follow Up and Current GVHD Status
In scenarios where an HCT was given after a cellular therapy and this form is now being completed based on the subsequent HCT date, these questions still apply and should be answered.

Question 182: Are symptoms of GVHD still present on the date of actual contact (or present at the time of death)?

This question refers to any symptoms of GVHD (acute and / or chronic) observed during the reporting period. This section of the form must be completed if the center reported Yes, acute, or chronic GVHD developed or persisted.

Indicate whether the recipient has active clinical signs / symptoms of acute and/or chronic GVHD on the date of contact. If the recipient has died, indicate whether GVHD symptoms were present at the time of death.

*Corticosteroids
Corticosteroids are captured differently depending on whether they are used topically or systemically. Use the following guidelines when determining how to report corticosteroids used to treat acute GVHD:
Topical Creams for Skin: Do not report topical ointments or creams used to treat skin GVHD including corticosteroid creams such as Triamcinolone or Hydrocortisone.
Other Topical Treatments: Certain corticosteroid treatments are inhaled or ingested, but are not absorbed and are therefore considered topical. Examples include beclomethasone and budesonide. Do not consider these medications when answering Is the recipient still taking systemic steroids.
Systemic Treatments: Systemic administration of corticosteroids, including use of prednisone and dexamethasone, should be reported in Is the recipient still taking systemic steroids.

Question 183: Is the recipient still taking systemic steroids? (Do not report steroids for adrenal insufficiency, ≤ 10 mg/day for adults, < 0.1 mg/kg/day for children)

This question is intended to capture if the recipient was still receiving systemic steroids (steroid dose > 10 mg / day for adults, > 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) for GVHD on the contact date.

Indicate if the recipient was still taking systemic steroids (steroid dose > 10 mg / day for adults, > 0.1 mg / kg / day for children, excluding steroids for adrenal insufficiency) on the contact date. Review the GVHD Reporting Instruction Overview for reporting instructions to these questions.

Questions 184 – 185: Date final treatment of systemic steroids administered

Indicate whether the date systemic steroids was discontinued is Known. If the final treatment date is Known, report the date when the final dose of systemic steroids was administered. For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

*Immunosuppressive Agents
As of December 9, 2023, questions regarding if the recipient is still taking immunosuppressive agents are required to be answered for all allogeneic infusions, regardless of if GVHD developed.

Question 186: Is the recipient still taking (non-steroid) immunosuppressive agents (including PUVA) for GVHD?

These questions are intended to capture if the recipient was still receiving non-steroid immunosuppressive agents for GVHD on the contact date.

Indicate if the recipient was still taking non-steroid immunosuppressive agents on the contact date. Review the GVHD Reporting Instruction Overview for reporting instructions to these questions.

Question 187 – 188: Date final treatment administered

Indicate whether the final administration date of non-steroidal immunosuppressive agents (including PUVA) is Known. If the final treatment date is Known, report the date when the final treatment or prophylaxis dose of non-steroidal immunosuppressive agents was administered.

For more information regarding reporting partial or unknown dates, see General Instructions, General Guidelines for Completing Forms.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.